Prosecution Insights
Last updated: November 20, 2026
Application No. 18/833,591

COMPOSITIONS OF AUTOPHAGY MODULATING AGENTS AND USES THEREOF

Non-Final OA §102§103§112
Filed
Jul 26, 2024
Priority
Jan 28, 2022 — provisional 63/304,151 +1 more
Examiner
BRAUN, MADELINE E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Washington University
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
1y 4m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
105 granted / 154 resolved
+8.2% vs TC avg
Strong +25% interview lift
Without
With
+25.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
43 currently pending
Career history
198
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
26.3%
-13.7% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
38.3%
-1.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 154 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of the invention of Group I (claims 1-10) and the species Ex. 97 (shown below) in the reply filed on 09/29/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). PNG media_image1.png 116 180 media_image1.png Greyscale Regarding applicant’s remarks, applicant is reminded that a timely filed traverse is required to preserve the right to petition. See MPEP 818.01(c) and 37 C.F.R. 1.144. Examiner searched the species of Ex. 97 and did not find art. Examiner expanded the search scope to the species of claim 6 and did not find art. Examiner further expanded the search to that of Ex. 3 and 6 in claim 5 and found art. Claims 1-10 read on the search scope. Claims 11-31 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/29/2026. Priority Examiner acknowledges that, according to the Filing receipt received 01/28/2025, that the instant application 18/833,591 filed 07/26/2024 is a 371 of PCT/US2023/061507 filed 01/27/2023, which claims benefit of U.S. provisional application 63/304,151 filed 01/28/2022. However, the limitations of the instant claims are not adequately supported or enabled in the manner provided by 35 U.S.C. 112(a) or pre-AIA U.S.C. 112, first paragraph by 63/304,151. More specifically, the limitations of R1 or R2, R2 or R3, or R3 or R4 optionally forming a substituted bicyclic group and Ex. 41-116 are not taught or suggested in their entirety by 63/304,151. Other deficiencies may be present. As such, all the instant claims have been awarded the effective filing date of PCT/US2023/061507 filed 01/27/2023. Information Disclosure Statement The Information Disclosure Statement filed on 07/26/2024 is in compliance with the provisions of 37 CFR 1.97 and has been considered in full. A signed copy of list of references cited from the IDS is included with this Office Action. Specification The disclosure is objected to because of the following informalities: page 44, lines 23-24, "intrathecal" is listed twice. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “wherein R1, R2, R3, R4, R5, or R6 is…”. The R variables are set forth in the alternative (i.e., “or”) which suggests that only one of R1-R6 needs to be one of the subsequently listed alternatives (“hydrogen… halo…”). It is therefore unclear whether each of R1-R6 are independently selected from the subsequent list of alternatives or if R1-R6 can be a different moiety that has not been listed. Correction is required. Regarding claim 1, the phrase "e.g." renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim 1 recites “C3-10cycloalkyl (e.g., phenyl)”, “halogen-substituted C3-10cycloalkyl (e.g., chlorophenyl)”, “C3-10cycloalkoxy (e.g., phenyl propoxy)”, and “alkoxy C3-10cycloalkyl (e.g., methoxy phenyl)”. However, phenyl is not a cycloalkyl as it aromatic and fully unsaturated. The instant specification does not clearly redefine cycloalkyl to include aryl groups, as such the scope of the claim is unclear. Claim 1 recites “halogen substituted C1-8alkyl (e.g., trifluoromethyl, trifluorobutoxy, trifluoropentoxy)”. However, neither butoxy nor pentoxy are alkyl groups. The scope of the claim is unclear. Claim 1 recites “R1 or R2, R2 or R3, or R3 or R4 optionally form a ring”. The alternative phrase “or” causes confusion as it is unclear how “R1 or R2” is intended to form a ring. Does only R1, R2, R3, or R4 form a ring (spirocyclic) or does applicant mean “R1 and R2, R2 and R3, or R3 and R4” form a ring fused to the core structure of formula (I)? For purposes of examination, the latter interpretation has been adopted by the examiner. However, correction is required. Claims 2-10 do not clarify the aforementioned limitations at issue and are also rejected. Claims 5 and 6 recite “or a pharmaceutically acceptable salt thereof, including all tautomers and stereoisomers, and optionally substituted analogs thereof”. This limitation is unclear as it cannot be ascertained whether “tautomers and stereoisomers, and optionally substituted analogs thereof” only pertains to the pharmaceutically acceptable salt or if tautomers, stereoisomers, and optionally substituted analogs of formula (I) are also within the scope of the claim. Claims 5 and 6 recite “optionally substituted analogs thereof”. The term “optionally substituted analog” renders the claims indefinite as analogs do not have a defined structure known in the art. Moreover, an analog that is “optionally substituted” provides for a virtually infinite number of compounds. One could not possibly envisage all the possibilities of an optionally substituted analog of any compound of the instant invention. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 2-6 and 8-10 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 2 sets forth compounds of Ex 48 and 97. Claim 4 sets forth Ex 97. Ex 48 and 97 are not within the scope of claim 1 as pyridinyl (substituted or unsubstituted) is not a listed alternative for R1-R6. Claims 2 and 3 recite “the autophagy modulating agent is… a 5,6-disubstituted quinolone”. This limitation does not clearly incorporate the limitations of the claim from which 2 and 3 depend, wherein “5,6-disubstituted” is broader in scope than the substituents set forth in claim 1 and “quinolone” does not delineate where the oxo substituent is located on the quinoline. Claims 5 and 6 recite “or a pharmaceutically acceptable salt thereof, including tautomers and stereoisomers, and optionally substituted analogs thereof”. However, these limitations are not within the scope of claim 1. Claims 5 and 6 therefore fail to incorporate the limitations of the claim from which they depend. Claim 5 sets forth compounds of Ex 11, 12, and 27. These compounds are not within the scope of claim 1 because halogen-substituted alkoxy is not a listed alternative for R1-R6. Claim 6 sets forth compounds of Ex 44, 45, 48, 53, 54, 56, 65, 67, 74, 75, 79, 80, 83, 84, 85, 86, 89, 90, 91, 93, 94, 95, 96, 97, 98, 99, 100, 102, 103, 107, 109, 110, 111, 114, 115, and 116. These compounds are not within the scope of claim 1 because thio or alkylthio, pyridinyl, substituted piperidinyl, piperazinyl, substituted pyrimidinyl, bridged heterocyclyl, fused heterocyclyl, and hydroxyl are not listed alternatives for R1-R6, nor can the carbons of the core quinolone be replaced with heteroatoms. Claims 8-10 set forth inherent properties and/or an intended use of the compounds of formula (I). Inherent properties do not further limit a claimed compound, nor is intended use given substantial patentable weight. These claims therefore fail to further limit the claim from which they depend. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1, 5, and 7-10 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Oh et al. (Nature Neuroscience; 2022). Oh et al. discloses a composition comprising the following compound in DMSO (p. 1426, Fig. 4). The compound is identical to that of Ex. 3 as in instant claim 5. PNG media_image2.png 172 206 media_image2.png Greyscale Oh et al. further discloses that G2-115 enhances autophagy and rescues medium spiny neurons from fibroblasts of patients with Huntington’s disease from degeneration (p. 1423, col. 2, par. 3). Claim(s) 1, 5, and 7-10 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Yoo et al. (US 2024/0011034 A1; effectively filed 2022). Yoo et al. discloses a composition comprising the following compound (Fig. 7A; p. 27-28 bridging paragraph [0151]). PNG media_image3.png 294 286 media_image3.png Greyscale Yoo et al. further discloses that G2-115 enhances autophagy and rescues medium spiny neurons from fibroblasts of patients with Huntington’s disease from degeneration (p. 27-28 bridging paragraph [0151]). The applied reference has a common assignee with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Claim Rejections - 35 USC § 102/103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 5, and 7-10 is/are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Zaragoza et al. (Journal of Medicinal Chemistry; 2005). Zaragoza et al. discloses a composition comprising 5,7-dichloro-2-quinolone in DMSO (p. 309, col. 1) which has the following structure (drawn by STN). PNG media_image4.png 173 240 media_image4.png Greyscale The compound is identical to that of Ex. 3 as in claim 5. While Zaragoza et al. is silent as to the properties of the above compound as an autophagy modulating agent having autophagy modulating activity, being an autophagy enhancing or pathway modulating agent, or being used to treat an autophagy-associated disease, disorder, or condition, MPEP 2112 states: “I. SOMETHING WHICH IS OLD DOES NOT BECOME PATENTABLE UPON THE DISCOVERY OF A NEW PROPERTY "[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer." Atlas Powder Co. v. IRECO Inc., 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). In In re Crish, 393 F.3d 1253, 1258, 73 USPQ2d 1364, 1368 (Fed. Cir. 2004), the court held that the claimed promoter sequence obtained by sequencing a prior art plasmid that was not previously sequenced was anticipated by the prior art plasmid which necessarily possessed the same DNA sequence as the claimed oligonucleotides. The court stated that "just as the discovery of properties of a known material does not make it novel, the identification and characterization of a prior art material also does not make it novel." Id.” Furthermore, while the claims are directed toward a composition, the properties as recited in the instant claims are that of the compound itself. Regarding properties and functions of identical structures, MPEP 2112.01 states: I. PRODUCT AND APPARATUS CLAIMS — WHEN THE STRUCTURE RECITED IN THE REFERENCE IS SUBSTANTIALLY IDENTICAL TO THAT OF THE CLAIMS, CLAIMED PROPERTIES OR FUNCTIONS ARE PRESUMED TO BE INHERENT Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. In re Best, 562 F.2d at 1255, 195 USPQ at 433. See also Titanium Metals Corp. v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985) (Claims were directed to a titanium alloy containing 0.2-0.4% Mo and 0.6-0.9% Ni having corrosion resistance. A Russian article disclosed a titanium alloy containing 0.25% Mo and 0.75% Ni but was silent as to corrosion resistance. The Federal Circuit held that the claim was anticipated because the percentages of Mo and Ni were squarely within the claimed ranges. The court went on to say that it was immaterial what properties the alloys had or who discovered the properties because the composition is the same and thus must necessarily exhibit the properties.). Since the compound of Zaragoza et al. is identical to that of Ex. 3 as in the instant claims, it is presumed that the two compounds necessarily share the same properties and/or functions. As such, the instantly claimed invention is anticipated by and/or prima facie obvious over the disclosure of Zaragoza et al. Claim(s) 1-3, 5, and 7-10 is/are rejected under 35 U.S.C. 102(a)(1) and (a)(2) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Neeb et al. (WO 2008/011551; 2008). Neeb et al. discloses a composition comprising the following compound (p. 47). PNG media_image5.png 138 166 media_image5.png Greyscale The compound is identical to that of Ex. 6 as in claim 5 and is a 5,6-disubstituted quinolone. While Neeb et al. is silent as to the properties of the above compound as an autophagy modulating agent having autophagy modulating activity, being an autophagy enhancing or pathway modulating agent, or being used to treat an autophagy-associated disease, disorder, or condition, MPEP 2112 states: “I. SOMETHING WHICH IS OLD DOES NOT BECOME PATENTABLE UPON THE DISCOVERY OF A NEW PROPERTY "[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer." Atlas Powder Co. v. IRECO Inc., 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). In In re Crish, 393 F.3d 1253, 1258, 73 USPQ2d 1364, 1368 (Fed. Cir. 2004), the court held that the claimed promoter sequence obtained by sequencing a prior art plasmid that was not previously sequenced was anticipated by the prior art plasmid which necessarily possessed the same DNA sequence as the claimed oligonucleotides. The court stated that "just as the discovery of properties of a known material does not make it novel, the identification and characterization of a prior art material also does not make it novel." Id.” Furthermore, while the claims are directed toward a composition, the properties as recited in the instant claims are that of the compound itself. Regarding properties and functions of identical structures, MPEP 2112.01 states: “I. PRODUCT AND APPARATUS CLAIMS — WHEN THE STRUCTURE RECITED IN THE REFERENCE IS SUBSTANTIALLY IDENTICAL TO THAT OF THE CLAIMS, CLAIMED PROPERTIES OR FUNCTIONS ARE PRESUMED TO BE INHERENT Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. In re Best, 562 F.2d at 1255, 195 USPQ at 433. See also Titanium Metals Corp. v. Banner, 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985) (Claims were directed to a titanium alloy containing 0.2-0.4% Mo and 0.6-0.9% Ni having corrosion resistance. A Russian article disclosed a titanium alloy containing 0.25% Mo and 0.75% Ni but was silent as to corrosion resistance. The Federal Circuit held that the claim was anticipated because the percentages of Mo and Ni were squarely within the claimed ranges. The court went on to say that it was immaterial what properties the alloys had or who discovered the properties because the composition is the same and thus must necessarily exhibit the properties.).” Since the compound of Neeb et al. is identical to that of Ex. 6 as in the instant claims, it is presumed that the two compounds necessarily share the same properties and/or functions. As such, the instantly claimed invention is anticipated by and/or prima facie obvious over the disclosure of Neeb et al. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MADELINE E BRAUN whose telephone number is (703)756-4533. The examiner can normally be reached M-F 8:30am-5:00pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MADELINE E BRAUN/Examiner, Art Unit 1624 10/22/2026
Read full office action

Prosecution Timeline

Jul 26, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799086
SMARCA DEGRADERS AND USES THEREOF
3y 3m to grant Granted Nov 17, 2026
Patent 12788759
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
4y 2m to grant Granted Nov 10, 2026
Patent 12780797
NOVEL QUINOLINE DERIVATIVE INHIBITOR
5y 8m to grant Granted Nov 03, 2026
Patent 12758543
COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIA
5y 5m to grant Granted Oct 13, 2026
Patent 12758516
COMPOUNDS FOR THE TREATMENT OF NEUROPATHIC PAIN
5y 0m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
94%
With Interview (+25.4%)
3y 8m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 154 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month